LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Corticosteroids Use in Pregnant Women with COVID-19: Recommendations from Available Evidence.

    Magala Ssekandi, Abdul / Sserwanja, Quraish / Olal, Emmanuel / Kawuki, Joseph / Bashir Adam, Mohammed

    Journal of multidisciplinary healthcare

    2021  Volume 14, Page(s) 659–663

    Abstract: Pregnant women experience immune system changes to accommodate and tolerate the growing foetus, these changes also increase their susceptibility to viral infections such as SARS-COV-2. COVID-19 in pregnancy increases the likelihood of hospital admission ... ...

    Abstract Pregnant women experience immune system changes to accommodate and tolerate the growing foetus, these changes also increase their susceptibility to viral infections such as SARS-COV-2. COVID-19 in pregnancy increases the likelihood of hospital admission and intensive care compared to non-pregnant women. Early administration of low-dose corticosteroids to patients with acute respiratory distress syndrome can reduce all-cause mortality among such patients. However, during pregnancy, prolonged use of corticosteroids that readily cross the placenta like dexamethasone can negatively impact both the mother and foetus. Evidence is thus needed on the choice, timing, and duration for corticosteroids use among pregnant women with COVID-19. This article aims to provide evidence on corticosteroid use in pregnant women with COVID-19. The RECOVERY trial deduced that low-dose dexamethasone (6 milligrams) reduced mortality by up to one-third among COVID-19 patients on mechanical ventilation and one-fifth among those who received supplemental oxygen. Pregnant women in this trial received either oral prednisolone or intravenous hydrocortisone. Based on the RECOVERY trial findings, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends that pregnant women with moderate-to-severe COVID-19 receive oral prednisolone or intravenous hydrocortisone. However, currently, the World Health Organisation (WHO) does not explicitly specify which corticosteroid to use among pregnant women with moderate-to-severe COVID-19. We also note that there are no published articles on corticosteroid use among pregnant women with severe COVID-19 in Africa.
    Language English
    Publishing date 2021-03-16
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2453343-9
    ISSN 1178-2390
    ISSN 1178-2390
    DOI 10.2147/JMDH.S301255
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Corticosteroids Use in Pregnant Women with COVID-19

    Magala Ssekandi A / Sserwanja Q / Olal E / Kawuki J / Bashir Adam M

    Journal of Multidisciplinary Healthcare, Vol Volume 14, Pp 659-

    Recommendations from Available Evidence

    2021  Volume 663

    Abstract: Abdul Magala Ssekandi,1 Quraish Sserwanja,2 Emmanuel Olal,3 Joseph Kawuki,4 Mohammed Bashir Adam2 ... School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong KongCorrespondence: Abdul Magala ...

    Abstract Abdul Magala Ssekandi,1 Quraish Sserwanja,2 Emmanuel Olal,3 Joseph Kawuki,4 Mohammed Bashir Adam2 1Gift Life Care Clinic, Lira, Uganda; 2Programmes Department, GOAL Global, Khartoum, Sudan; 3Yotkom Medical Centre, Kitgum, Uganda; 4Centre for Health Behaviours Research, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong KongCorrespondence: Abdul Magala SsekandiGift Life Care Clinic Lira, UgandaTel +256784612652Email ssekandi91@gmail.comAbstract: Pregnant women experience immune system changes to accommodate and tolerate the growing foetus, these changes also increase their susceptibility to viral infections such as SARS-COV-2. COVID-19 in pregnancy increases the likelihood of hospital admission and intensive care compared to non-pregnant women. Early administration of low-dose corticosteroids to patients with acute respiratory distress syndrome can reduce all-cause mortality among such patients. However, during pregnancy, prolonged use of corticosteroids that readily cross the placenta like dexamethasone can negatively impact both the mother and foetus. Evidence is thus needed on the choice, timing, and duration for corticosteroids use among pregnant women with COVID-19. This article aims to provide evidence on corticosteroid use in pregnant women with COVID-19. The RECOVERY trial deduced that low-dose dexamethasone (6 milligrams) reduced mortality by up to one-third among COVID-19 patients on mechanical ventilation and one-fifth among those who received supplemental oxygen. Pregnant women in this trial received either oral prednisolone or intravenous hydrocortisone. Based on the RECOVERY trial findings, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends that pregnant women with moderate-to-severe COVID-19 receive oral prednisolone or intravenous hydrocortisone. However, currently, the World Health Organisation (WHO) does not explicitly specify which corticosteroid to use among pregnant women with moderate-to-severe COVID-19. We also note that there are no published articles on corticosteroid use among pregnant women with severe COVID-19 in Africa.Keywords: COVID-19, corticosteroids, pregnant-women, prednisolone, preterm birth
    Keywords covid-19 ; corticosteroids ; pregnant-women ; prednisolone ; preterm birth ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2021-03-01T00:00:00Z
    Publisher Dove Medical Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top